Press releases

Sobi™ to acquire Synagis® US rights from AstraZeneca - creates a platform for global growth

Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) has entered into agreements to acquire the perpetual rights to Synagis® (palivizumab) in the US from AstraZeneca and to...

11/13/2018 - 08:00
Regulatory

Swedish Orphan Biovitrum AB (publ) (Sobi™) today announces the results for the third quarter 2018. Total revenues grew 45 per cent compared with Q3 2017 (34 per cent at constant exchange rates (CER)) and amounted to SEK 2,315 M. EBITA was SEK 933 M, an increase of 74...

10/31/2018 - 08:00
Regulatory

On 31 October, at 08:00 CET, Swedish Orphan Biovitrum AB (publ) (Sobi™) will publish its report for the third quarter 2018.

Financial analysts and media are invited to participate in a telephone conference, which will include a presentation of the results, on the same...

10/23/2018 - 10:30

Sobi™ Cycle bike ride from Mainz to Brussels raises funds, awareness for haemophilia

A team of cyclists from Sobi™ have biked from Mainz to Brussels 2-4 October to help raise funds for people with haemophilia as well as awareness about the condition.

SobiCycle 2018 is...

10/04/2018 - 14:00

Swedish Orphan Biovitrum AB (publ) (Sobi™) releases the primary efficacy results from the phase 2 study with anakinra in patients with acute gout – the anaGO study. For the primary endpoint of patient assessed pain intensity in the most affected joint there was a...

10/03/2018 - 08:00
Regulatory

Press contacts

Subscribe to our press releases and financial reports